Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 7—July 2017
Research Letter

Live Cell Therapy as Potential Risk Factor for Q Fever

Maja GeorgeComments to Author , Andreas Reich, Klaus Cussler, Herrmann Jehl, and Florian Burckhardt
Author affiliations: Author affiliations: Robert Koch Institute, Berlin, Germany (M. George); European Centre for Disease Prevention and Control, Stockholm, Sweden (M. George); Institute for Infectious Disease Prevention Landau, Landau, Germany (M. George, F. Burckhardt); Bavarian Health and Food Safety Authority, Oberschleissheim, Germany (A. Reich); Paul Ehrlich Institut, Langen, Germany (K. Cussler); Health Department of the Bad Duerckheim District, Bad Duerkheim, Germany (H. Jehl)

Main Article

Figure

Residential (n = 11), occupational (n = 10), and recipient (n = 1) cases of Q fever related to live cell therapy (LCT), by week of symptom onset compatible with Q fever, Rhineland-Palatinate, Germany, 2014.

Figure. Residential (n = 11), occupational (n = 10), and recipient (n = 1) cases of Q fever related to live cell therapy (LCT), by week of symptom onset compatible with Q fever, Rhineland-Palatinate, Germany, 2014.

Main Article

Page created: June 19, 2017
Page updated: June 19, 2017
Page reviewed: June 19, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external